Literature DB >> 12643166

Antiobesity drugs: current and future issues.

M Ammar Hatahet1, Nikhil V Dhurandhar.   

Abstract

Overweight and obesity affect more than 60% of the population in the United States. Many social and environmental factors influence this phenomenon. Because of the tremendous difficulties associated with addressing these factors, health care providers have been looking for a magic pill that resolves this tissue. Although there is no panacea, this article is intended to concisely review commonly prescribed medications for obesity, their efficacy, and side effects. In addition, some pharmacologic agents with a promising antiobesity action are discussed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12643166     DOI: 10.1007/s11892-002-0105-3

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  66 in total

1.  Early leptin response to a palatable diet predicts dietary obesity in rats: key role of melanocortin-4 receptors in the ventromedial hypothalamic nucleus.

Authors:  J A Harrold; G Williams; P S Widdowson
Journal:  J Neurochem       Date:  2000-03       Impact factor: 5.372

2.  Anorectic drugs and valvular heart disease: a biological and clinical perspective.

Authors:  J Wong; S S Reddy; A L Klein
Journal:  Cleve Clin J Med       Date:  1998-01       Impact factor: 2.321

Review 3.  Nutritional regulation of leptin in humans.

Authors:  R A Coleman; T S Herrmann
Journal:  Diabetologia       Date:  1999-06       Impact factor: 10.122

4.  Ghrelin strongly stimulates growth hormone release in humans.

Authors:  K Takaya; H Ariyasu; N Kanamoto; H Iwakura; A Yoshimoto; M Harada; K Mori; Y Komatsu; T Usui; A Shimatsu; Y Ogawa; K Hosoda; T Akamizu; M Kojima; K Kangawa; K Nakao
Journal:  J Clin Endocrinol Metab       Date:  2000-12       Impact factor: 5.958

5.  Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion.

Authors:  Tomomi Shiiya; Masamitsu Nakazato; Masanari Mizuta; Yukari Date; Muhtashan S Mondal; Muneki Tanaka; Shin-Ichi Nozoe; Hiroshi Hosoda; Kenji Kangawa; Shigeru Matsukura
Journal:  J Clin Endocrinol Metab       Date:  2002-01       Impact factor: 5.958

6.  Ghrelin is a growth-hormone-releasing acylated peptide from stomach.

Authors:  M Kojima; H Hosoda; Y Date; M Nakazato; H Matsuo; K Kangawa
Journal:  Nature       Date:  1999-12-09       Impact factor: 49.962

7.  Ghrelin-producing cells exist as two types of cells, closed- and opened-type cells, in the rat gastrointestinal tract.

Authors:  Ichiro Sakata; Kazuaki Nakamura; Mami Yamazaki; Maki Matsubara; Yuijiro Hayashi; Kenji Kangawa; Takafumi Sakai
Journal:  Peptides       Date:  2002-03       Impact factor: 3.750

Review 8.  Sibutramine. A review of its contribution to the management of obesity.

Authors:  W McNeely; K L Goa
Journal:  Drugs       Date:  1998-12       Impact factor: 9.546

9.  Sibutramine: a new weight loss agent without evidence of the abuse potential associated with amphetamines.

Authors:  J O Cole; A Levin; B Beake; P E Kaiser; M L Scheinbaum
Journal:  J Clin Psychopharmacol       Date:  1998-06       Impact factor: 3.153

10.  Weight-reducing effects of the plasma protein encoded by the obese gene.

Authors:  J L Halaas; K S Gajiwala; M Maffei; S L Cohen; B T Chait; D Rabinowitz; R L Lallone; S K Burley; J M Friedman
Journal:  Science       Date:  1995-07-28       Impact factor: 47.728

View more
  1 in total

1.  Intestinal electric stimulation decreases fat absorption in rats: therapeutic potential for obesity.

Authors:  Ying Sun; Jiande Chen
Journal:  Obes Res       Date:  2004-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.